MADRIGAL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount of $44.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxExemptIncome · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2025 was $44.01M, a 342.11% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2024 was $9.95M, a 20.12% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax exempt income, amount for fiscal 2023 was $8.29M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount 12 month |
|---|---|
| 2025-12-31 | $44.01M 10-K · filed 2026-02-19 |
| 2024-12-31 | $9.95M 10-K · filed 2026-02-19 |
| 2023-12-31 | $8.29M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |